



**NEUROLOGY PHASE II
Steering Committee Meeting
October 3-4, 2012**

National Quality Forum
Executive Building
1030 15th Street, NW, Suite 900
Washington, DC 20005
(202) 783-1300

DRAFT AGENDA

Day 1: October 3, 2012

- 9:00am **Welcome**
David Knowlton, MA, Co-chair
David Tirschwell, MD, Co-chair
Karen Johnson, MS, Senior Director
- 9:10am **Introductions and Disclosure of Interest**
Ann Hammersmith, JD, General Counsel
- 9:25am **Project Introduction and Overview of Evaluation Process**
Karen Johnson, MS, Senior Director
Suzanne Theberge, MPH, Project Manager
- 9:40am **Consideration of Candidate Measures**
- 2111: Antipsychotic Use in Persons with Dementia (Pharmacy Quality Alliance)
 - 2091: Persistent Indicators of Dementia without a Diagnosis—Long Stay (AMDA)
 - 2092: Persistent Indicators of Dementia without a Diagnosis—Short Stay (AMDA)
- 11:00am **Break**
- 11:15am **Consideration of Candidate Measures (Continued)**
- 1973: Annual Parkinson's Disease Diagnosis Review (AAN)
 - 1982: Parkinson's Disease Psychiatric Disorders or Disturbance Assessment (AAN)

- 1983: Parkinson’s Disease Cognitive Impairment or Dysfunction Assessment (AAN)
- 12:15pm **NQF Member and Public Comment**
- 12:30pm **Lunch**
- 1:15pm **Consideration of Candidate Measures (Continued)**
- 1985: Parkinson’s Disease: Querying About Sleep Disturbances (AAN)
 - 1988: Parkinson’s Disease Rehabilitative Therapy Options (AAN)
 - 1989: Parkinson’s Disease Medical and Surgical Treatment Options Reviewed (AAN)
- 3:00pm **Break**
- 3:15pm **Consideration of Candidate Measures (Continued)**
- 1814: Counseling for Women of Childbearing Potential with Epilepsy (American Academy of Neurology [AAN])
 - 1953: Seizure type(s) and current seizure frequency(ies) (AAN)
 - 1954: Documentation of Etiology of Epilepsy or Epilepsy Syndrome (AAN)
- 4:45pm **NQF Member and Public Comment**
- 5:00 pm **Adjourn**

Day 2: October 4, 2012

- 8:30am **Welcome, Recap of Day 1**
- 8:40am **Consideration of Candidate Measures (Continued)**
- 0507: Stenosis measurement in carotid imaging studies (American Medical Association - Physician Consortium for Performance Improvement [AMA-PCPI])
 - 2009: Dementia: Neuropsychiatric Symptom Assessment (AMA-PCPI)
 - 2011: Dementia: Management of Neuropsychiatric Symptoms (AMA-PCPI)
 - 2016: Dementia: Screening for Depressive Symptoms (AMA-PCPI)
 - 1990: Dementia: Staging of Dementia (AMA-PCPI)

- 10:15am **Break**
- 10:30am **Consideration of Candidate Measures (Continued)**
- 2000: Dementia: Cognitive Assessment (AMA-PCPI)
 - 2004: Dementia: Functional Status Assessment (AMA-PCPI)
 - 2028: Dementia: Counseling regarding Safety Concerns (AMA-PCPI)
 - 2029: Dementia: Counseling regarding Risks of Driving (AMA-PCPI)
 - 2030: Dementia: Caregiver Education and Support (AMA-PCPI)
- 11:45pm **NQF Member and Public Comment**
- 12:00pm **Lunch**
- 12:30pm **Additional Discussion Topics**
- Measure gaps
 - Disparities-sensitive measures
- 1:30pm **Additional Discussion Topics: Phase 1 Follow-Up**
- Discussion of comments received during second comment period on Yale/CMS Stroke Mortality & Readmissions measures
- 2:30pm **NQF Member and Public Comment**
- 2:45pm **Next Steps/Committee Timeline**
- 3:00pm **Adjourn**